SRZN NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 3.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.18 (down 99.4%), Surrozen, Inc. would be worth roughly what it owes.
Total debt $6.3M against a stock market value of $204.0M.
Distance to default 3.41 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.2M (short-term plus half of long-term), stock volatility 108.8%; Altman Z'' -31.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchsâ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-Ã, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| COLUMN GROUP III GP, | X-InTheMoney | 485,830 | $11.60 | 2026-10-20 |
| COLUMN GROUP III GP, | X-InTheMoney | 548,653 | $11.60 | 2026-10-20 |
| COLUMN GROUP III GP, | X-InTheMoney | 517,241 | $11.60 | 2026-10-20 |
| COLUMN GROUP III GP, | X-InTheMoney | 775,861 | $11.60 | 2026-10-20 |
| COLUMN GROUP III GP, | X-InTheMoney | 242,915 | $11.54 | 2026-10-20 |